About Akums
Akums is a company based in Delhi (India) founded in 2004. Akums has raised $70 million across 1 funding round from investors including Quadria Capital. The company has 17,860 employees as of March 31, 2024. Akums has completed 2 acquisitions, including Ankur Drugs and Parabolic Drugs. Akums operates in a competitive market with competitors including Jubilant Life Sciences, Recipharm, Unither, Nectar Lifesciences and CoreRx, among others.
- Headquarter Delhi, India
- Employees 17860 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Akums Drugs And Pharmaceuticals Limited
-
Annual Revenue
$481.07 M (USD)-1.44as on Mar 31, 2024
-
Net Profit
$39.49 M (USD)8476.7as on Mar 31, 2024
-
EBITDA
$54.09 M (USD)-4.46as on Mar 31, 2024
-
Total Equity Funding
$70 M (USD)
in 1 rounds
-
Latest Funding Round
$70 M (USD), Private Equity Round
Nov 13, 2019
- Investors
-
Employee Count
17860
as on Mar 31, 2024
-
Investments & Acquisitions
Ankur Drugs
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Akums
Akums is a publicly listed company on the NSE with ticker symbol AKUMS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Akums
Unlock access to complete
Funding Insights of Akums
Akums has successfully raised a total of $70M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $70 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Akums
Akums has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Quadria Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare private equity investments focused on Asian markets.
|
Locked | Locked | Locked |
Investor details for Akums
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Akums
Akums has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Ankur Drugs and Parabolic Drugs.
Investment portfolio details for Akums
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CMO specializing in cephalosporins and beta-lactams
|
Locked | Locked | 1997 | Locked | |
|
APIs, intermediates, and formulations are manufactured and exported.
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for Akums
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Akums
Detailed financials for Akums
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Akums Comparisons
Peer comparison for Akums
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Akums
Akums operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jubilant Life Sciences, Recipharm, Unither, Nectar Lifesciences and CoreRx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Company offering a suite of R&D and manufacturing services for small molecules and generics
|
|
| Locked | Locked | Locked |
Pharmaceutical development and manufacturing services are offered contractually.
|
|
| Locked | Locked | Locked |
Contract development and manufacturing organization for proprietary and generic drugs
|
|
| Locked | Locked | Locked |
Cephalosporin APIs and generic formulations are manufactured.
|
|
| Locked | Locked | Locked |
CDMO with a focus on early phase drug product development
|
Detailed competitors of Akums
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Akums
Complete news archive for Akums
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Akums
Akums was founded in 2004 and raised its 1st funding round 15 years after it was founded.
Akums is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
Akums is a funded company, having raised a total of $70M across 1 funding round to date.
As of Mar 31, 2024, the latest employee count at Akums is 17,860.
Annual revenue of Akums is $481.07M as on Mar 31, 2024.
Akums was founded in 2004 and is headquartered in Delhi, India. As a contract development and manufacturing organization in the pharmaceutical sector, formulations are produced and exported across multiple dosage forms, including oral solids, liquids, sterile injectables, hormonals, ointments, cosmetics, Ayurvedics, and nutraceuticals. Therapeutic areas addressed encompass respiratory, neurology, analgesics, cardiovascular, immunomodulators, and supportive care.
Akums's top competitors include Jubilant Life Sciences, Nectar Lifesciences and Windlas.
Yes, Akums is publicly traded on NSE under the ticker symbol AKUMS.
Akums has made 2 acquisitions, including Ankur Drugs, and Parabolic Drugs.
Akums has 1 investor. Key investors include Quadria Capital.
The ticker symbol of Akums is AKUMS on NSE.
The valuation of Akums is $459.31M as of Nov 2019.